New developments in laboratory monitoring of HIV-1 infection

Clinical Microbiology and Infection

Volumn 8, Issue 3, 2002, Pages 137-143

  Telenti, A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Drug resistance; Immune recovery; Inhibitory quotient; Pharmacogenetics; Therapeutic drug monitoring; Viral fitness

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; CYTOCHROME P450 2D6; MULTIDRUG RESISTANCE PROTEIN 1; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; CELL COUNT; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INDIVIDUALIZATION; LABORATORY TEST; MEDICAL RESEARCH; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036489741     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2002.00408.x     Document Type: Review

References (49)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. Plasma load and CD4 lymphocytes as prognostic markers of HIV-1 infection
3. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study
4. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy
5. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients
6. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy
7. Virological and immunological characteristics of HIV treatment failure
8. Fitness of antiretroviral drug resistant HIV-1
9. Immunologic and virologic status after 14-18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort
10. In vitro replication kinetics of human immunodeficiency virus type 1 variants in relation to virus load in long-term survivors of HIV-1 infection
11. Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection
12. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression
13. Natural variation of replication capacity measurements in drug naive/susceptible HIV-1
14. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination
15. Acute HIV infection: Impact on the spread of HIV transmission of drug resistance
16. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
17. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
18. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
19. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1
20. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy
21. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
22. Prevalence and predictive value of intermittent viremia with combination HIV therapy
23. Detection of low HIV-1 RNA levels in plasma
24. Highly active antiretroviral therapy: Low rates of clinical disease progression despite high rates of virological failure
25. HIV treatment failure: Testing for HIV resistance in clinical practice
26. The virtual phenotype is an independent predictor of clinical response
27. Antiretroviral drug resistance testing in adult HIV-1 infection-Recommendations of an International AIDS Society-USA panel
28. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transpcriptase inhibitor efavirenz by high-performance liquid solid-phase extraction
29. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
30. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: High inter-patient and low intrapatient variability
31. Response to antiretroviral therapy in HIV-infected individuals carrying allelic variants of the multidrug resistant transporter MDR1
32. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data
33. Response to ritonavir intensification in indinavir recipients is highly correlated with virtual inhibitory quotient
34. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
35. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy
36. AIDS opportunistic illnesses occurring after initiation of highly active antiretroviral therapy: The Swiss HIV Cohort Study
37. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study
38. Changes in thymic function with age and during the treatment of HIV infection
39. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
40. Identification of a human recent thymic emigrant phenotype
41. Recurrences of cytornegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution
42. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
43. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression
44. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant
45. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10
46. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage
47. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS
48. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1
49. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study